Zenas BioPharma, Inc. (ZBIO)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 63 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops immunology-based medicines for autoimmune and inflammatory diseases. FY2025 revenue was $10.0 million. Its clinical-stage pipeline centers on antibody and fusion-protein programs rather than marketed drug franchises.
Today's Snapshot
ZBIO closed 2.3% lower at 32.29. Zenas BioPharma discussed its drug pipeline and available cash at a Citi-hosted investor summit.
Trading Volume
Below 10d avg (526.2K)
385.3K
vs S&P 500 Today
Underperforming Market
-1.82%
Updated: September 10, 2026 at 12:15 UTC
Peers & Related Assets
Get premium market insights delivered directly to your inbox.